دورية أكاديمية
Detection of second primary lymphoma in late diffuse large B-cell lymphoma recurrences
| العنوان: | Detection of second primary lymphoma in late diffuse large B-cell lymphoma recurrences |
|---|---|
| المؤلفون: | Berendsen, M.R., Bladel, D.A.G. van, Hesius, E., Groot, F.A. de, Kroeze, L.I., Rijntjes, J., Luijks, J.A.C.W., Hoevenaars, B., Halilovic, A., Nooijen, P., Bladel, E. van, Jonge-Peeters, S. de, Lensen, C., Pruijt, H., Spek, E.V., Vermaat, J.S.P., Hess, C., Hebeda, K.M., Stevens, W.B.C., Krieken, J.H.J.M. van, Brand, M.V., Groenen, P.J.T.A., Scheijen, B. |
| المصدر: | Modern Pathology |
| سنة النشر: | 2023 |
| المجموعة: | Leiden Repository (Leiden University) |
| مصطلحات موضوعية: | clonality analysis, diffuse large B-cell lymphoma, immunoglobulin gene, rearrangements, relapse, second primary lymphoma |
| الوصف: | Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) relapse and often require salvage chemotherapy followed by autologous stem cell transplantation. In most cases, the clonal relationship between the first diagnosis and subsequent relapse is not assessed, thereby potentially missing the identification of second primary lymphoma. In this study, the clonal rela-tionship of 59 paired DLBCL diagnoses and recurrences was established by next-generation sequencing-based detection of immunoglobulin gene rearrangements. Among 50 patients with interpretable results, 43 patients (86%) developed clonally related relapsed disease. This was observed in 100% of early recurrences (<2 years), 80% of the recurrences with an interval between 2 and 5 years, and 73% of late recurrences (>= 5 years). On the other hand, 7 (14%) out of 50 patients displayed different dominant clonotypes in primary DLBCL and clinical recurrences, confirming the occurrence of second primary DLBCL; 37% of DLBCL recurrences that occurred >= 4 years after diagnosis were shown to be second primary lymphomas. The clonally unrelated cases were Epstein-Barr virus positive in 43% of the cases, whereas this was only 5% in the relapsed DLBCL cases. In conclusion, next-generation sequencing-based clonality testing in late recurrences should be considered in routine diagnostics to distinguish relapse from second primary lymphoma, as this latter group of patients with DLBCL may benefit from less-intensive treatment strategies.(c) 2023 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY license (http://creativecommons.orgTest/ licenses/by/4.0/). ; Immunobiology of allogeneic stem cell transplantation and immunotherapy of hematological diseases |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | lumc-id: 178120890; https://hdl.handle.net/1887/3590626Test |
| DOI: | 10.1016/j.modpat.2023.100119 |
| الإتاحة: | https://doi.org/10.1016/j.modpat.2023.100119Test https://hdl.handle.net/1887/3590626Test |
| رقم الانضمام: | edsbas.59FAD7AE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.modpat.2023.100119 |
|---|